Evotec and Novo Nordisk forms collaboration to develop novel small molecule therapies
Shots:
- The partnership will focus on indications like diabetes- obesity- co morbidities including nonalcoholic steatohepatitis (NASH)- cardiovascular diseases- and diabetic kidney disease
- Evotec’s drug-discovery platform will be used in ligand-based design to produce products for patients
- Also the Evotec’s INDiGO platform will be used by Novo- to perform IND registration through pre-clinical studies. Financial details were not disclosed
Ref: Evotec | Image: Cyprotex
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com